Chitosan Interferon-γ Nanogene Therapy for Lung Disease: Modulation of T-Cell and Dendritic Cell Immune Responses

Allergy, Asthma and Clinical Immunology

Volumn 4, Issue 3, 2008, Pages 95-105

  Kong, Xiaoyuan ^a   Hellermann, Gary R ^a   Zhang, Weidong ^a   Jena, Prasanna ^a   Kumar, Mukesh ^a   Behera, Aruna ^a   Behera, Sumita ^a   Lockey, Richard ^a,b   Mohapatra, Shyam S ^a  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Allergy; Asthma; Interferon

Indexed keywords

EID: 84873285120     PISSN: 17101484     EISSN: 17101492     Source Type: Journal    
DOI: 10.1186/1710-1492-4-3-95     Document Type: Article

References (49)

1. Behera AK, Kumar M, Lockey RF, Mohapatra SS. Adenovirus-mediated interferon gamma gene therapy for allergic asthma: involvement of interleukin 12 and STAT4 signaling. Hum Gene Ther 2002, 13:1697-709. 10.1089/104303402760293547, 12396623.
2. Monahan PE, Samulski RJ. AAV vectors: is clinical success on the horizon?. Gene Ther 2000, 7:24-30. 10.1038/sj.gt.3301109, 10680012.
3. Senior K. Adeno-associated virus vectors under scrutiny. Lancet 2002, 359(9313):1216. 10.1016/S0140-6736(02)08258-2, 11955549.
4. Zaiss AK, Liu Q, Bowen GP, et al. Differential activation of innate immune responses by adenovirus and adeno-associated virus vectors. J Virol 2002, 76:4580-90. 10.1128/JVI.76.9.4580-4590.2002, 155101, 11932423.
5. Zhao N, Liu DP, Liang CC. Hot topics in adeno-associated virus as a gene transfer vector. Mol Biotechnol 2001, 19:229-37. 10.1385/MB:19:3:229, 11721619.
6. Cohen AD, Boyer JD, Weiner DB. Modulating the immune response to genetic immunization. FASEB J 1998, 12:1611-26.
7. Donnelly JJ, Ulmer JB, Liu MA. DNA vaccines. Dev Biol Stand 1998, 95:43-53.
8. Erbacher P, Zou S, Bettinger T, et al. Chitosan-based vector/DNA complexes for gene delivery: biophysical characteristics and transfection ability. Pharm Res 1998, 15:1332-9. 10.1023/A:1011981000671, 9755882.
9. Lee KY, Kwon IC, Kim YH, et al. Preparation of chitosan self-aggregates as a gene delivery system. J Control Release 1998, 51:213-20. 10.1016/S0168-3659(97)00173-9, 9685919.
10. Leong KW, Mao HQ, Truong-Le VL, et al. DNA-polycation nanospheres as non-viral gene delivery vehicles. J Control Release 1998, 53:183-93. 10.1016/S0168-3659(97)00252-6, 9741926.
11. Richardson SC, Kolbe HV, Duncan R. Potential of low molecular mass chitosan as a DNA delivery system: biocompatibility, body distribution and ability to complex and protect DNA. Int J Pharm 1999, 178:231-43. 10.1016/S0378-5173(98)00378-0, 10205643.
12. Roy K, Mao HQ, Huang SK, Leong KW. Oral gene delivery with chitosan--DNA nanoparticles generate immunologic protection in a murine model of peanut allergy. Nat Med 1999, 5:387-91. 10.1038/7385, 10202926.
13. Nishimura K, Nishimura S, Nishi N, et al. Immunological activity of chitin and its derivatives. Vaccine 1984, 2:93-9. 10.1016/S0264-410X(98)90039-1, 6397928.
14. Otterlei M, Varum KM, Ryan L, Espevik T. Characterization of binding and TNF-alpha-inducing ability of chitosans on monocytes: the involvement of CD14. Vaccine 1994, 12:825-32. 10.1016/0264-410X(94)90292-5, 7526573.
15. Muzzarelli R, Baldassarre V, Conti F, et al. Biological activity of chitosan: ultrastructural study. Biomaterials 1988, 9:247-52. 10.1016/0142-9612(88)90092-0, 3408796.
16. Pappineau A, Hoover D, Knoor D, Farkas D. Food biotechnol. New York (NY); Marcel Dekker 1991, 5:45-7.
17. Aspden TJ, Mason JD, Jones NS, et al. Chitosan as a nasal delivery system: the effect of chitosan solutions on in vitro and in vivo mucociliary transport rates in human turbinates and volunteers. J Pharm Sci 1997, 86:509-13. 10.1021/js960182o, 9109057.
18. Bodmeier R, Chen HG, Paeratakul O. A novel approach to the oral delivery of micro- or nanoparticles. Pharm Res 1989, 6:413-7. 10.1023/A:1015987516796, 2748533.
19. Illum L, Farraj NF, Davis SS. Chitosan as a novel nasal delivery system for peptide drugs. Pharm Res 1994, 11:1186-9. 10.1023/A:1018901302450, 7971722.
20. Miyazaki S, Nakayama A, Oda M, et al. Chitosan and sodium alginate based bioadhesive tablets for intraoral drug delivery. Biol Pharm Bull 1994, 17:745-7.
21. Tozaki H, Komoike J, Tada C, et al. Chitosan capsules for colon-specific drug delivery: improvement of insulin absorption from the rat colon. J Pharm Sci 1997, 86:1016-21. 10.1021/js970018g, 9294815.
22. Artursson P, Lindmark T, Davis SS, Illum L. Effect of chitosan on the permeability of monolayers of intestinal epithelial cells (Caco-2). Pharm Res 1994, 11:1358-61. 10.1023/A:1018967116988, 7816770.
23. Coyle AJ, Tsuyuki S, Bertrand C, et al. Mice lacking the IFN-gamma receptor have impaired ability to resolve a lung eosinophilic inflammatory response associated with a prolonged capacity of T cells to exhibit a Th2 cytokine profile. J Immunol 1996, 156:2680-5.
24. Romagnani S. Lymphokine production by human T cells in disease states. Annu Rev Immunol 1994, 12:227-57. 10.1146/annurev.iy.12.040194.001303, 8011282.
25. Wenner CA, Guler ML, Macatonia SE, et al. Roles of IFN-gamma and IFN-alpha in IL-12-induced T helper cell-1 development. J Immunol 1996, 156:1442-7.
26. Szeto C, Gillespie KM, Mathieson PW. Levamisole induces interleukin-18 and shifts type 1/type 2 cytokine balance. Immunology 2000, 100:217-24. 10.1046/j.1365-2567.2000.00042.x, 2327010, 10886398.
27. Gao Y, Chenping Z, Lin XP. [Aerosolized recombinant interferon-gamma prevent antigen-induced eosinophil recruitment in guinea pig trachea]. Zhonghua Jie He He Hu Xi Za Zhi 1997, 20:287-90.
28. Boraschi D, Censini S, Bartalini M, et al. Interferons inhibit LTC4 production in murine macrophages. J Immunol 1987, 138:4341-6.
29. Chen H, Munakata M, Amishima M, et al. Gamma-interferon modifies guinea pig airway functions in vitro. Eur Respir J 1994, 7:74-80. 10.1183/09031936.94.07010074, 8143835.
30. Pouw Kraan TC, Boeije LC, de Groot ER, et al. Reduced production of IL-12 and IL-12-dependent IFN-gamma release in patients with allergic asthma. J Immunol 1997, 158:5560-5.
31. Daines MO, Hershey GK. A novel mechanism by which interferon-gamma can regulate interleukin (IL)-13 responses. Evidence for intracellular stores of IL-13 receptor alpha-2 and their rapid mobilization by interferon-gamma. J Biol Chem 2002, 277:10387-93. 10.1074/jbc.M108109200, 11786536.
32. Ford JG, Rennick D, Donaldson DD, et al. IL-13 and IFN-gamma: interactions in lung inflammation. J Immunol 2001, 167:1769-77.
33. Krasnowska M, Medrala W, Malolepszy J, Krasnowski R. Effect of recombinant IFN-gamma on IgE-dependent leukotriene generation by peripheral blood leukocytes in patients with pollinosis and asthma. Arch Immunol Ther Exp (Warsz) 2000, 48:287-92.
34. Pierkes M, Bellinghausen I, Hultsch T, et al. Decreased release of histamine and sulfidoleukotrienes by human peripheral blood leukocytes after wasp venom immunotherapy is partially due to induction of IL-10 and IFN-gamma production of T cells. J Allergy Clin Immunol 1999, 103(2 Pt 1):326-32. 10.1016/S0091-6749(99)70509-9, 9949326.
35. Gurujeyalakshmi G, Giri SN. Molecular mechanisms of antifibrotic effect of interferon gamma in bleomycin-mouse model of lung fibrosis: downregulation of TGF-beta and procollagen I and III gene expression. Exp Lung Res 1995, 21:791-808. 10.3109/01902149509050842, 8556994.
36. Cohen J. IL-12 deaths: explanation and a puzzle. Science 1995, 270:908. 10.1126/science.270.5238.908a, 7481785.
37. Mohapatra SS. IL-12 possibilities. Science 1995, 269:1499. 10.1126/science.7667628, 7667628.
38. Hogan SP, Foster PS, Tan X, Ramsay AJ. Mucosal IL-12 gene delivery inhibits allergic airways disease and restores local antiviral immunity. Eur J Immunol 1998, 28:413-23. 10.1002/(SICI)1521-4141(199802)28:02<413::AID-IMMU413>3.0.CO;2-1, 9521048.
39. Murray HW. Current and future clinical applications of interferon-gamma in host antimicrobial defense. Intensive Care Med 1996, 22(Suppl 4):S456-61. 10.1007/BF01743724, 8923089.
40. Sur S, Lam J, Bouchard P, et al. Immunomodulatory effects of IL-12 on allergic lung inflammation depend on timing of doses. J Immunol 1996, 157:4173-80.
41. Dow SW, Schwarze J, Heath TD, et al. Systemic and local interferon gamma gene delivery to the lungs for treatment of allergen-induced airway hyperresponsiveness in mice. Hum Gene Ther 1999, 10:1905-14. 10.1089/10430349950017266, 10466624.
42. Li XM, Chopra RK, Chou TY, et al. Mucosal IFN-gamma gene transfer inhibits pulmonary allergic responses in mice. J Immunol 1996, 157:3216-9.
43. Okubo T, Hagiwara E, Ohno S, et al. Administration of an IL-12-encoding DNA plasmid prevents the development of chronic graft-versus-host disease (GVHD). J Immunol 1999, 162:4013-7.
44. Tovey MG, Maury C. Oromucosal interferon therapy: marked antiviral and antitumor activity. J Interferon Cytokine Res 1999, 19:145-55. 10.1089/107999099314298, 10090400.
45. Kumar M, Behera AK, Lockey RF, et al. Intranasal gene transfer by chitosan-DNA nanospheres protects BALB/c mice against acute respiratory syncytial virus infection. Hum Gene Ther 2002, 13:1415-25. 10.1089/10430340260185058, 12215263.
46. Kumar M, Kong X, Behera AK, et al. Chitosan IFN-gamma-pDNA nanoparticle (CIN) therapy for allergic asthma. Genet Vaccines Ther 2003, 1:3. 10.1186/1479-0556-1-3, 280670, 14613519.
47. Laliotou B, Duncan L, Dick AD. Intranasal administration of retinal antigens induces transient T cell activation and apoptosis within drainage lymph nodes but not spleen. J Autoimmun 1999, 12:145-55. 10.1006/jaut.1998.0269, 10222024.
48. Badovinac VP, Tvinnereim AR, Harty JT. Regulation of antigen-specific CD8+ T cell homeostasis by perforin and interferon-gamma. Science 2000, 290:1354-58. 10.1126/science.290.5495.1354, 11082062.
49. Lohman BL, Welsh RM. Apoptotic regulation of T cells and absence of immune deficiency in virus-infected gamma interferon receptor knockout mice. J Virol 1998, 72:7815-21. 110096, 9733817.